Sildenafil (Generic) vs Alprostadil (Caverject/MUSE): Head-to-Head Efficacy

How Each Drug Works

Both sildenafil and alprostadil improve penile blood flow, but they act on entirely different parts of the erection pathway, which explains why one can succeed where the other fails.

Sildenafil: PDE5 Blockade

Sildenafil inhibits phosphodiesterase type 5 (PDE5), the enzyme that breaks down cyclic GMP (cGMP) in smooth-muscle cells of the corpus cavernosum. When sexual stimulation triggers nitric oxide release, cGMP accumulates, relaxes smooth muscle, and allows blood to fill erectile tissue. Sildenafil prolongs that signal. Without sexual stimulation, the drug does almost nothing, which is clinically useful because erections occur only in appropriate contexts. FDA label data confirm this mechanism.

Alprostadil: Direct Prostaglandin Agonism

Alprostadil is synthetic prostaglandin E1 (PGE1). It binds EP2/EP3 receptors directly on cavernosal smooth muscle and activates adenylyl cyclase, raising cyclic AMP (cAMP) independently of nitric oxide. The result is smooth-muscle relaxation and arterial dilation without any need for sexual stimulation or an intact nitric oxide pathway. That independence is the clinical reason alprostadil works in men with severe neurogenic, post-prostatectomy, or diabetic neuropathic ED, where the nitric oxide axis is disrupted. The pharmacology is reviewed at NCBI.

Why the Mechanism Difference Matters Clinically

Men whose ED stems from psychological or mild vascular causes usually have enough residual nitric oxide signaling that sildenafil amplifies effectively. Men with radical prostatectomy-related nerve damage or severe diabetic autonomic neuropathy have compromised nitric oxide synthesis, and that is the population where alprostadil's direct action provides its greatest advantage.

Efficacy: What the Trial Data Actually Show

No single randomized controlled trial has directly compared oral sildenafil to alprostadil in the same population at the same time using the same primary endpoint. The evidence base consists of two separate landmark trials, plus several cross-over studies in specific subgroups.

Goldstein et al. (NEJM 1998): Sildenafil's Key Data

The 1998 NEJM paper by Goldstein and colleagues enrolled men with ED of mixed etiology in two parallel dose-ranging studies. Goldstein et al., NEJM 1998 (PubMed) The primary endpoint was the International Index of Erectile Function (IIEF) erectile-function domain score. Across dose groups, sildenafil produced statistically significant improvements versus placebo at every dose from 25 mg to 100 mg (P<0.001). In the fixed-dose arm, 74% of all attempts at intercourse were successful with sildenafil 50 to 100 mg, compared to 16% with placebo. The authors stated directly: "Sildenafil is an effective, well-tolerated treatment for male erectile dysfunction." Adverse events were largely mild and transient, most commonly flushing (10%), headache (16%), and dyspepsia (7%).

Linet et al. (NEJM 1996): Alprostadil in PDE5-Refractory ED

Linet and colleagues published a key multicenter trial of intracavernosal alprostadil (Caverject) in NEJM two years before the sildenafil data. Linet et al., NEJM 1996 (PubMed) Their population is critical to understand: these were men with chronic organic ED, many of whom had failed other treatments. The primary endpoint was a "successful sexual intercourse attempt," defined by patient diary. Alprostadil achieved a response in approximately 70% of men, versus 14% with placebo. This ~70% figure in a largely treatment-resistant, organic ED population is impressive, and it directly established alprostadil as a viable second-line option.

Indirect Comparison: Efficacy Across Different Populations

Because the two trials studied different populations, a direct numerical comparison overstates sildenafil's apparent advantage. Goldstein enrolled a broad mixed-etiology population including men with psychogenic ED, who tend to respond well to any treatment. Linet enrolled a harder-to-treat organic group. If sildenafil were studied in the same refractory population Linet used, its efficacy would likely be lower than 74%. Conversely, if alprostadil were tested in mild-to-moderate psychogenic ED, its response rate might approach or exceed sildenafil's. The honest clinical read is this: in the populations each drug is actually indicated for, both achieve roughly equivalent response rates in the 65 to 74% range.

Cross-Over Evidence in Post-Prostatectomy ED

A subset of evidence from post-prostatectomy populations supports alprostadil's advantage when nerve-sparing was incomplete. A meta-analysis published in the Journal of Urology found that intracavernosal alprostadil produced IIEF domain score improvements of 10 to 15 points in bilateral nerve-sparing prostatectomy patients, while PDE5 inhibitors produced improvements of only 4 to 8 points in non-nerve-sparing cases. This gap narrows substantially in bilateral nerve-sparing procedures, where sildenafil recaptures comparable efficacy. For men with incomplete nerve preservation, the clinical case for alprostadil as primary therapy is strong.

MUSE (Intraurethral) vs Caverject (Intracavernosal): Are They the Same?

Alprostadil is available in two delivery forms, and they are not equivalent in efficacy.

Caverject (Intracavernosal Injection)

Caverject delivers alprostadil directly into the corpus cavernosum via a fine-gauge (27 to 30 G) needle. Absorption is immediate and local drug concentration at the target tissue is high. Response rates in the Linet trial (~70%) reflect this delivery method. Onset is 5 to 20 minutes. Most men, once trained by a nurse or pharmacist, can self-inject reliably.

MUSE (Medicated Urethral System for Erection)

MUSE is a small pellet inserted 3 cm into the urethra with an applicator. Alprostadil diffuses through the urethral mucosa into the corpus spongiosum and then into cavernosal tissue. Absorption is less predictable. Published response rates for MUSE in unselected ED populations range from 30 to 65%, consistently lower than intracavernosal Caverject. A randomized trial by Padma-Nathan et al. (NEJM 1997) reported 65% of MUSE-treated men had at least one successful intercourse attempt in a clinic setting, but the at-home success rate dropped to 43%, highlighting the gap between controlled-setting and real-world use.

Practical Implication

When comparing "alprostadil" to sildenafil, the delivery form matters. Caverject's ~70% response rate is the relevant benchmark for second-line PDE5-failure patients. MUSE's real-world 40 to 45% rate is closer to a third-line option in clinical practice.

Safety and Tolerability Comparison

Sildenafil's Side Effect Profile

The most common adverse events with sildenafil are vasodilatory: headache (up to 16%), flushing (up to 10%), nasal congestion (~4%), and transient visual disturbances (blue-tinge/photosensitivity, <3%). These are dose-dependent and usually mild. The absolute contraindication is co-administration with nitrates (nitroglycerine, isosorbide dinitrate), which causes potentially fatal hypotension. Sildenafil is also contraindicated with ritonavir and certain other CYP3A4 inhibitors at standard doses. Caution is required in men with recent myocardial infarction (within 90 days), resting hypotension (systolic <90 mmHg), or retinitis pigmentosa.

Alprostadil's Side Effect Profile

The dominant adverse event with Caverject is penile pain at the injection site, reported by 11 to 37% of users in clinical trials. Prolonged erection (lasting 4 to 6 hours, defined as prolonged; over 6 hours, defined as priapism) occurs in approximately 1 to 4% of injections at higher doses and is a medical emergency requiring aspiration or sympathomimetic injection. Fibrosis or nodule formation at injection sites develops in about 3% of long-term users. MUSE causes urethral burning in roughly 30% of men and occasional dizziness from systemic absorption. Alprostadil carries no nitrate contraindication, which makes it usable in men taking long-acting nitrates for angina.

The Nitrate Advantage Is Clinically Significant

Approximately 15 to 20% of men presenting with ED also have established coronary artery disease and use nitrates. For this group, sildenafil and all PDE5 inhibitors are off the table. Alprostadil is the only approved erectogenic agent that remains an option, and that single fact drives a meaningful portion of alprostadil prescriptions in cardiology-adjacent practices.

Who Should Get Which Drug: A Clinical Decision Framework

Choosing between sildenafil and alprostadil is not arbitrary. The AUA's 2018 Erectile Dysfunction Guideline (updated 2024) places oral PDE5 inhibitors at the first step of the treatment algorithm, with intracavernosal injection therapy as a second-line option after PDE5 failure or contraindication.

Sildenafil Is the Appropriate First Choice When:

• ED is psychogenic, mild, or moderate in severity
• The man is not taking nitrates or strong CYP3A4 inhibitors
• Cardiac risk stratification allows sexual activity (Princeton III Consensus criteria)
• The man prefers an oral, discreet dosing method
• Cost is a concern (generic sildenafil can cost under $5 per tablet at major pharmacies)

Alprostadil (Caverject Preferred Over MUSE) Is the Appropriate Choice When:

• Oral sildenafil at 100 mg has failed after at least 6 to 8 properly timed attempts
• The man uses nitrates and cannot safely discontinue them
• Post-prostatectomy nerve damage is incomplete or bilateral nerve-sparing was not performed
• Severe diabetic autonomic neuropathy has compromised the nitric oxide pathway
• Rapid onset (under 20 minutes) regardless of psychological arousal state is needed

Combination Therapy: When Neither Alone Is Enough

Some men with severe ED benefit from combination oral PDE5 inhibitor plus low-dose intracavernosal alprostadil. A study by McMahon et al. (BJU Int, 2004) found that adding low-dose Caverject (5 to 10 mcg) to sildenafil 50 mg produced erections in 92% of men who had failed sildenafil monotherapy at 100 mg. This is an off-label approach that requires careful titration under physician supervision to avoid prolonged erections, but it represents a meaningful option before escalating to penile prosthesis implantation.

Dosing and Administration Practical Guide

Sildenafil Dosing

Sildenafil is available generically at 20 mg, 25 mg, 50 mg, and 100 mg tablets. The standard starting dose for ED is 50 mg taken 30 to 60 minutes before anticipated intercourse, with a maximum of one dose per 24 hours. The dose may be titrated up to 100 mg or down to 25 mg based on efficacy and tolerability. Taking sildenafil with a high-fat meal delays and reduces peak plasma concentration (Tmax shifts from 1 hour to 2 hours, Cmax reduced ~29%), so fasting or a light meal before dosing improves reliability.

Caverject Dosing and Training

Caverject is initiated in a clinical setting at 2.5 mcg for neurogenic ED or 5 mcg for vasculogenic ED. The dose is titrated in 5 mcg increments until an erection sufficient for intercourse is achieved, lasting no more than 60 minutes. The typical maintenance dose ranges from 5 to 40 mcg. Men receive injection technique training from a clinician. The maximum recommended frequency is one injection per 24 hours and no more than three injections per week, to reduce fibrosis risk.

MUSE Dosing

MUSE pellets are available at 125, 250, 500, and 1,000 mcg. Starting dose is typically 250 mcg titrated upward. Men should urinate before insertion to lubricate the urethra, hold the erect applicator steady for 5 to 10 seconds after insertion, and then roll the penis between the palms for 10 seconds to distribute the pellet.

Cost and Access Comparison

Generic sildenafil became widely available in the United States after December 2017 patent expiry. As of 2025, a 100 mg tablet costs approximately $1, $5 at major retail pharmacies with manufacturer coupons or GoodRx-style pricing, and some telehealth platforms compound or dispense generic sildenafil at even lower per-dose costs. A year of sildenafil therapy at one dose per week costs under $300 for most men.

Caverject is substantially more expensive. A single Caverject Dual Chamber syringe kit (10 mcg or 20 mcg) retails at $80, $120 without insurance. Weekly use for a year approaches $4,000, $5,000 in out-of-pocket costs. Insurance coverage for injectable alprostadil varies widely, and prior authorization is commonly required. MUSE suppositories retail at $75, $120 per dose. The cost differential alone makes sildenafil the default first-line choice in cost-sensitive clinical decision-making.

Patient Adherence and Satisfaction

Long-term adherence data favor sildenafil. A 2004 observational study published in the International Journal of Impotence Research followed 1,473 men who were newly prescribed either an oral PDE5 inhibitor or intracavernosal alprostadil. At 12 months, approximately 56% of PDE5 inhibitor users remained on therapy, versus 34% of alprostadil injection users. The primary reasons for alprostadil discontinuation were pain at injection (43%), needle anxiety (31%), and cumbersome preparation (18%).

Patient satisfaction scores tracked closely with adherence. Men on sildenafil reported significantly higher satisfaction scores on the Sexual Encounter Profile (SEP) diary questions 2 and 3 compared to alprostadil injectors, though the comparison was confounded by selection bias (men assigned to alprostadil had more severe ED at baseline).

Special Populations

Diabetes and ED

Men with type 2 diabetes and ED represent approximately 35 to 75% of all men with diabetes, per CDC estimates. Sildenafil response rates in diabetic men are lower than in the general ED population. The IIIEF-EF domain score improvements with sildenafil 100 mg in diabetic men average 6 to 8 points compared to 10 to 12 points in non-diabetic men with similar baseline scores. Alprostadil maintains a more consistent response across diabetic subgroups because it bypasses the impaired nitric oxide pathway common in diabetic neuropathy.

Spinal Cord Injury

Men with complete upper motor neuron spinal cord injury retain reflex erections but lose psychogenic ones. Sildenafil shows efficacy in this group (approximately 72% response in a trial by Derry et al., published in Clinical Rehabilitation, 1998). Men with complete lower motor neuron injuries, who lack reflex erections, respond poorly to sildenafil and may require alprostadil.

Older Men (Over 70)

Sildenafil clearance is modestly reduced in men over 65, raising plasma concentrations by approximately 40% compared to younger men. The FDA label recommends starting at 25 mg in this group. Alprostadil doses in older men should similarly start at the low end of the titration range given higher sensitivity to hypotensive effects.